TERMIS 2021 | The industrialization of regenerative medicine

Laura Niklason, MD, PhD, Yale University, New Haven, CT & Humacyte, Durham, NC, describes the mass manufacturing of advanced therapies, including bioengineered human vessels. Various stimuli, as well as growth and physical factors were identified that can successfully stimulate the growth of new arteries from vascular cells. Dr Niklason emphasizes the need to keep those conditions constant to industrialize the production of blood vessels, and instead of scaling up, a scaling out approach should be adopted, where the manufacturing process is repeated in multiple bioreactors. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).